Format

Send to

Choose Destination
J Clin Pathol. 2015 Nov;68(11):913-6. doi: 10.1136/jclinpath-2015-202978. Epub 2015 Jul 8.

New tumour antigen PLAC1/CP1, a potentially useful prognostic marker and immunotherapy target for gastric adenocarcinoma.

Author information

1
Department of Pathology, Peking University People's Hospital, Beijing, China.
2
Department of Statistics Office, Peking University Health Science Center, Beijing, China.
3
Department of Clinical Epidemiology, Peking University People's Hospital, Beijing, China.

Abstract

AIM:

To evaluate protein expression and clinical significance of PLAC1/CP1 antigen in primary gastric adenocarcinoma.

METHODS:

Protein expression of PLAC1/CP1 was analysed by tissue chip and immunohistochemistry in surgical specimens obtained from 119 patients with gastric cancer. The data were analysed using SPSS V.16.0 software applying the χ(2) test and Kaplan-Meier method.

RESULTS:

The positive expression frequency of PLAC1/CP1 protein was 61.3% (73/119 patients). The overall survival of patients with PLAC1/CP1 protein-positive expression was significantly lower than that of patients with PLAC1/CP1 protein-negative expression (p<0.05). There was no significant relationship between PLAC1/CP1 expression and patient gender, age, tumour position, tumour size, differentiation, gross type, lymph node or TNM stage.

CONCLUSIONS:

PLAC1/CP1 protein is expressed in over half of cases of primary gastric cancer, and PLAC1/CP1 protein expression is inversely correlated with patient survival. The data indicate that PLAC1/CP1 provides a marker for identifying gastric cancers with poor prognosis, and suggest that PLAC1/CP1 may provide a useful target for immunotherapy.

KEYWORDS:

GASTRIC CANCER; IMMUNOHISTOCHEMISTRY; PROTEINS; TUMOUR IMMUNITY; TUMOUR MARKERS

PMID:
26157147
DOI:
10.1136/jclinpath-2015-202978
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center